Homevideos Newshealthcare News

    Pfizer-BioNTech vaccine trial: US FDA publishes positive initial analysis

    videos | IST

    Pfizer-BioNTech vaccine trial: US FDA publishes positive initial analysis

    Mini

    Pfizer and AstraZeneca have released additional data from their trials on the efficacy of the vaccines. The US drug regulator has released its positive initial analysis on the Pfizer-BioNTech vaccine saying the two-dose vaccine is "highly effective" in preventing symptomatic COVID-19.

    Pfizer and AstraZeneca have released additional data from their trials on the efficacy of the vaccines.
    The US drug regulator has released its positive initial analysis on the Pfizer-BioNTech vaccine saying the two-dose vaccine is "highly effective" in preventing symptomatic COVID-19.
    Key analysis was that the vaccine starts providing protection 10 days after the first dose itself. It is at least 52 percent effective before the second dose, meaning even if people miss their second dose they may get some protection from transmission although how long this immunity will last is still unclear.
    CNBC-TV18’s Archana Shukla brings more details.
    Watch this video for more.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    next story

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng